Minute Insight: Xeltis Expects The US Trial Of 'Living' Vascular Graft To Start This Year
Executive Summary
Xeltis hemodialysis access graft, made of its proprietary electrospun supramolecular polymer material, is advancing in clinical trials in Europe and will likely be ready for a US trial by the end of this year, according to the company.
You may also be interested in...
Minute Insight: Xeltis’ Vascular Access Graft Stays Patent In First-In-Human Trial
Xeltis’ aXess graft demonstrated high patency rates and no infections after six months in the first-in-human trial.
EU Investment Looks To Regenerate Tissue, As Well As Its Economy
Xeltis, a Netherlands-based company producing cardiovascular implants to stimulate natural regeneration of biological tissue, has received funding from the European Union’s rescue fund.
EuroPCR 2017: Xeltis' Regenerated Heart Valve Shows Promising Early Preclinical Data
It may still be early days but Xeltis' second product from its Endogenous Tissue Restoration platform technology, an aortic valve scaffold, is showing promising results in animal studies. The data, presented at EuroPCR, showed that the bioresorbable aortic valve had good hemodynamic performance and fully functional valves in vivo six months after implantation.